Patents by Inventor Ashwin U. Rao
Ashwin U. Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250026762Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).Type: ApplicationFiled: November 28, 2022Publication date: January 23, 2025Applicant: Merck Sharp & Dohme LLCInventors: Mark E. Fraley, Tao Liang, H. Marie Loughran, Anthony J. Roecker, Kathy M. Schirripa, Ling Tong, Ashwin U. Rao
-
Publication number: 20240287138Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, can inhibit TNFR1 and are expected to have utility as therapeutic agents, for example, for treating inflammatory bowel diseases, rheumatoid arthritis, junvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of inflammatory bowel diseases, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa, and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: February 1, 2024Publication date: August 29, 2024Inventors: Kaustav Biswas, Nicolas C. Boyer, Brandon D. Cash, Fa-Xiang Ding, John R. Frost, Michael B. Garrigou, James P. Jewell, Ahmet Kekec, Hu-Jung Julie Lee, Songnian Lin, Ashwin U. Rao, Daniel J. Sindhikara, Murray Wan, Yuping Zhu, Susan L. Zultanski, Tony Siu, Andrew M. Haidle, Claudio Mapelli, Luca Gambini, Federica Orvieto, Roberta Tozzi, Nicolo Maria Pasquini, Luigi Abate, Giordano Proietti, Michael Wuo, Ryan Chau
-
Patent number: 10875851Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: GrantFiled: November 13, 2017Date of Patent: December 29, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
-
Publication number: 20190352294Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: ApplicationFiled: November 13, 2017Publication date: November 21, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
-
Publication number: 20180215729Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: ApplicationFiled: March 28, 2018Publication date: August 2, 2018Inventors: Anandan PALANI, Xianhai HUANG, Dong XIAO, Sunil PALIWAL, Hon-Chung TSUI, Michelle Laci WROBLESKI, Ashwin U. RAO, Cheng WANG, Sapna S. SHAH, Neng-Yang SHIH
-
Patent number: 9969711Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: GrantFiled: October 14, 2016Date of Patent: May 15, 2018Assignee: OPKO Health, Inc.Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
-
Publication number: 20170029403Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: ApplicationFiled: October 14, 2016Publication date: February 2, 2017Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
-
Patent number: 9469629Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: GrantFiled: June 13, 2014Date of Patent: October 18, 2016Assignee: OPKO Health, Inc.Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
-
Patent number: 9290454Abstract: The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.Type: GrantFiled: September 26, 2013Date of Patent: March 22, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Xianhai Huang, Anandan Palani, Ashwin U. Rao, Hongjun Zhang, Wei Zhou
-
Publication number: 20150353498Abstract: The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.Type: ApplicationFiled: September 26, 2013Publication date: December 10, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Xianhai Huang, Anandan Palani, Ashwin U. Rao, Hongjun Zhang, Wei Zhou
-
Patent number: 8927559Abstract: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.Type: GrantFiled: October 6, 2011Date of Patent: January 6, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Robert G. Aslanian, Christopher W. Boyce, Robert D. Mazzola, Jr., Brian A. McKittrick, Kevin D. McCormick, Anandan Palani, Jun Qin, Haiqun Tang, Dong Xiao, Younong Yu, John P. Caldwell, Elizabeth Helen Kelley, Hongjun Zhang, Phieng Siliphaivanh, Rachel N. MacCoss, Joey L. Methot, Jolicia Polivina Gauuan, Qin Jiang, Andrew J. Leyhane, Purakkattle Johny Biju, Li Dong, Xianhai Huang, Ning Shao, Wei Zhou, Pawan K. Dhondi, Ashwin U. Rao
-
Publication number: 20140296196Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
-
Patent number: 8754216Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: GrantFiled: September 26, 2011Date of Patent: June 17, 2014Assignee: OPKO Health, Inc.Inventors: Sapna S. Shah, Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Neng-Yang Shih
-
Patent number: 8569312Abstract: In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: GrantFiled: April 4, 2013Date of Patent: October 29, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier, Jie Wu, Junying Zheng, Younong Yu, Jianhua Chao, Walter S. Won, Ashwin U. Rao, Rongze Kuang, Pauline C. Ting, Xianhai Huang, Ning Shao, Anandan Palani, Michael Y. Berlin, Robert G. Aslanian
-
Patent number: 8476274Abstract: In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: GrantFiled: October 18, 2012Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier, Jie Wu, Junying Zheng, Younong Yu, Jianhua Chao, Walter S. Won, Ashwin U. Rao, Rongze Kuang, Pauline C. Ting, Xianhai Huang, Ning Shao, Anandan Palani, Michael Y. Berlin, Robert G. Aslanian
-
Patent number: 8324213Abstract: In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.Type: GrantFiled: October 6, 2009Date of Patent: December 4, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier, Jie Wu, Junying Zheng, Youngong Yu, Jianhua Chao, Walter S. Won, Ashwin U. Rao, Rongze Kuang, Pauline C. Ting, Xianhai Huang, Ning Shao, Anandan Palani, Michael Y. Berlin, Robert G. Aslanian
-
Publication number: 20120295879Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.Type: ApplicationFiled: September 26, 2011Publication date: November 22, 2012Applicant: OPKO HEALTH, INC.Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sapna S. Shah, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Neng-Yang Shih
-
Patent number: 8283360Abstract: The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.Type: GrantFiled: December 18, 2009Date of Patent: October 9, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Anandan Palani, Ashwin U. Rao, Xiao Chen, Ning Shao, Ying R. Huang, Robert G. Aslanian
-
Publication number: 20120225885Abstract: The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.Type: ApplicationFiled: November 12, 2010Publication date: September 6, 2012Inventors: Ashwin U. Rao, Anandan Palani, Robert G. Aslanian
-
Publication number: 20110319434Abstract: The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.Type: ApplicationFiled: December 18, 2009Publication date: December 29, 2011Applicant: Schering Plough CorporationInventors: Anandan Palani, Ashwin U. Rao, Xiao Chen, Ning Shao, Ying R. Huang, Robert G. Aslanian